Amgen Inc. (NASDAQ:AMGN) Shares Sold by Peloton Wealth Strategists

Peloton Wealth Strategists lessened its stake in Amgen Inc. (NASDAQ:AMGNFree Report) by 3.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,201 shares of the medical research company’s stock after selling 718 shares during the period. Amgen accounts for about 2.1% of Peloton Wealth Strategists’ holdings, making the stock its 16th biggest position. Peloton Wealth Strategists’ holdings in Amgen were worth $4,707,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Profund Advisors LLC increased its stake in Amgen by 7.4% in the 2nd quarter. Profund Advisors LLC now owns 43,146 shares of the medical research company’s stock valued at $9,579,000 after buying an additional 2,980 shares during the period. Pinnacle Wealth Management LLC purchased a new stake in shares of Amgen in the second quarter valued at about $1,521,000. Gamco Investors INC. ET AL increased its stake in shares of Amgen by 2.3% during the second quarter. Gamco Investors INC. ET AL now owns 5,696 shares of the medical research company’s stock worth $1,265,000 after acquiring an additional 128 shares during the period. Nelson Capital Management LLC lifted its position in Amgen by 1.2% in the second quarter. Nelson Capital Management LLC now owns 18,471 shares of the medical research company’s stock valued at $4,101,000 after purchasing an additional 217 shares during the period. Finally, Edgestream Partners L.P. boosted its holdings in Amgen by 250.3% in the 2nd quarter. Edgestream Partners L.P. now owns 5,391 shares of the medical research company’s stock valued at $1,197,000 after purchasing an additional 3,852 shares in the last quarter. 74.44% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, major shareholder Amgen Inc acquired 1,764,705 shares of the firm’s stock in a transaction on Tuesday, September 19th. The stock was bought at an average cost of $17.00 per share, with a total value of $29,999,985.00. Following the transaction, the insider now directly owns 35,368,653 shares in the company, valued at approximately $601,267,101. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Amgen news, major shareholder Amgen Inc bought 1,764,705 shares of Amgen stock in a transaction dated Tuesday, September 19th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $29,999,985.00. Following the purchase, the insider now owns 35,368,653 shares in the company, valued at approximately $601,267,101. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $272.81, for a total transaction of $2,728,100.00. Following the completion of the sale, the executive vice president now directly owns 28,078 shares in the company, valued at $7,659,959.18. The disclosure for this sale can be found here. Insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Leerink Partnrs raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research note on Wednesday, October 11th. StockNews.com began coverage on shares of Amgen in a report on Thursday, October 5th. They issued a “strong-buy” rating for the company. SVB Leerink raised Amgen from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $267.00 to $318.00 in a research note on Wednesday, October 11th. UBS Group reduced their price objective on Amgen from $272.00 to $268.00 and set a “neutral” rating for the company in a report on Thursday, November 2nd. Finally, Morgan Stanley lowered their target price on Amgen from $300.00 to $291.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $278.15.

Check Out Our Latest Analysis on AMGN

Amgen Trading Up 0.1 %

Shares of Amgen stock traded up $0.33 during trading hours on Monday, reaching $265.72. The stock had a trading volume of 301,461 shares, compared to its average volume of 2,466,537. The firm has a market capitalization of $142.21 billion, a price-to-earnings ratio of 18.86, a P/E/G ratio of 2.61 and a beta of 0.58. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $291.60. The company has a current ratio of 2.86, a quick ratio of 2.56 and a debt-to-equity ratio of 7.71. The firm has a 50 day simple moving average of $269.59 and a two-hundred day simple moving average of $247.47.

Amgen (NASDAQ:AMGNGet Free Report) last released its quarterly earnings data on Tuesday, October 31st. The medical research company reported $4.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.65 by $0.31. The company had revenue of $6.90 billion during the quarter, compared to analyst estimates of $6.92 billion. Amgen had a net margin of 28.20% and a return on equity of 165.37%. The business’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.70 earnings per share. As a group, equities research analysts anticipate that Amgen Inc. will post 18.65 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be given a dividend of $2.13 per share. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $8.52 dividend on an annualized basis and a dividend yield of 3.21%. Amgen’s payout ratio is currently 60.55%.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.